Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
International Journal of Radiation Oncology, Biology, Physics|March 16, 2026
Tumor purity as a prognostic and predictive biomarker of postoperative radiotherapy outcomes in stage IIIA-N2 non-small-cell lung cancer: a transcriptomic analysis from the Lung ART trialWael S Zrafi, Víctor Albarrán-Artahona, Filippo G Dall'Olio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2022
Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes studyZ R Reichert, T M Morgan, G Li, et al.
Therapeutic Advances in Medical Oncology|February 17, 2022
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLCFilippo G Dall'Olio, Claudia Parisi, Laura Marcolin, et al.
Clinical Lung Cancer|April 14, 2021
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint InhibitorsFilippo G Dall'Olio, Francesco Gelsomino, Nicole Conci, et al.
Journal for Immunotherapy of Cancer|November 29, 2024
Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancerFilippo G Dall'Olio, Wael Salem Zrafi, Quentin Blampey, et al.
ESMO Open|November 18, 2025
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50A De Giglio, L Zullo, A Di Federico, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung CancerFilippo G Dall'Olio, Wael Zrafi, Damien Vasseur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 17, 2021
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapyA Cortellini, B Ricciuti, F Facchinetti, et al.
Journal for Immunotherapy of Cancer|February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinationsAlessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2024
Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological CorrelatesFilippo G Dall'Olio, Wael Zrafi, Veronique Roelants, et al.
Pageof 5